Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230507488> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4230507488 endingPage "1014" @default.
- W4230507488 startingPage "1014" @default.
- W4230507488 abstract "1014 Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. P is an immune checkpoint inhibitor and HTMB is an emerging predictive biomarker for checkpoint inhibitor therapy. Results in a cohort of MBC pts with HTMB treated with P are reported. Methods: Eligible pts had advanced cancer, no standard treatment options, ECOG PS 0-1, measurable disease and acceptable organ function. Genomic testing was performed using commercially available tests selected by sites. Pts matched to P had HTMB defined as ≥9 mutations/megabase (Muts/Mb) by a FoundationOne test (n=20) or approved by the TAPUR Molecular Tumor Board for other tests (n=8). A Simon two-stage design was used to test a null rate of 15% vs. 35% (power = 0.85; α = 0.10). If ≥2 of 10 pts in stage 1 have disease control (DC) (objective response (OR) or stable disease at 16 weeks (wks) (SD16+)), an additional 18 pts are enrolled. If ≥7 of 28 pts have DC, the drug is considered worthy of further study. Secondary endpoints are progression-free survival (PFS), overall survival (OS) and safety. Results: Twenty-eight female MBC pts were enrolled from October 2016 to July 2018. Pts received P at 2 mg/kg (n=8) or 200 mg (n=20) IV over 30 minutes, every 3 wks. HTMB ranged from 9 to 37 Muts/Mb. Demographics and outcomes are summarized in Table (N=28). No relationship was observed between #Muts/Mb and PFS or OS. Two grade 3 AEs (weight loss and hypoalbuminemia) and 1 grade 2 SAE (urinary tract infection) were reported as at least possibly related to P. Conclusions: P demonstrated anti-tumor activity in heavily pre-treated MBC pts with HTMB . Additional study of P is warranted in MBC pts with HTMB. Clinical trial information: NCT02693535. [Table: see text]" @default.
- W4230507488 created "2022-05-11" @default.
- W4230507488 creator A5010433429 @default.
- W4230507488 creator A5021269424 @default.
- W4230507488 creator A5027903860 @default.
- W4230507488 creator A5029296725 @default.
- W4230507488 creator A5029412691 @default.
- W4230507488 creator A5031299191 @default.
- W4230507488 creator A5040035667 @default.
- W4230507488 creator A5042358497 @default.
- W4230507488 creator A5044876102 @default.
- W4230507488 creator A5048916805 @default.
- W4230507488 creator A5050130060 @default.
- W4230507488 creator A5051758545 @default.
- W4230507488 creator A5052563056 @default.
- W4230507488 creator A5053172275 @default.
- W4230507488 creator A5053535513 @default.
- W4230507488 creator A5054246379 @default.
- W4230507488 creator A5058562764 @default.
- W4230507488 creator A5066700940 @default.
- W4230507488 creator A5081311878 @default.
- W4230507488 creator A5091895679 @default.
- W4230507488 date "2019-05-20" @default.
- W4230507488 modified "2023-09-29" @default.
- W4230507488 title "Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study." @default.
- W4230507488 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.1014" @default.
- W4230507488 hasPublicationYear "2019" @default.
- W4230507488 type Work @default.
- W4230507488 citedByCount "26" @default.
- W4230507488 countsByYear W42305074882019 @default.
- W4230507488 countsByYear W42305074882020 @default.
- W4230507488 countsByYear W42305074882021 @default.
- W4230507488 countsByYear W42305074882022 @default.
- W4230507488 countsByYear W42305074882023 @default.
- W4230507488 crossrefType "journal-article" @default.
- W4230507488 hasAuthorship W4230507488A5010433429 @default.
- W4230507488 hasAuthorship W4230507488A5021269424 @default.
- W4230507488 hasAuthorship W4230507488A5027903860 @default.
- W4230507488 hasAuthorship W4230507488A5029296725 @default.
- W4230507488 hasAuthorship W4230507488A5029412691 @default.
- W4230507488 hasAuthorship W4230507488A5031299191 @default.
- W4230507488 hasAuthorship W4230507488A5040035667 @default.
- W4230507488 hasAuthorship W4230507488A5042358497 @default.
- W4230507488 hasAuthorship W4230507488A5044876102 @default.
- W4230507488 hasAuthorship W4230507488A5048916805 @default.
- W4230507488 hasAuthorship W4230507488A5050130060 @default.
- W4230507488 hasAuthorship W4230507488A5051758545 @default.
- W4230507488 hasAuthorship W4230507488A5052563056 @default.
- W4230507488 hasAuthorship W4230507488A5053172275 @default.
- W4230507488 hasAuthorship W4230507488A5053535513 @default.
- W4230507488 hasAuthorship W4230507488A5054246379 @default.
- W4230507488 hasAuthorship W4230507488A5058562764 @default.
- W4230507488 hasAuthorship W4230507488A5066700940 @default.
- W4230507488 hasAuthorship W4230507488A5081311878 @default.
- W4230507488 hasAuthorship W4230507488A5091895679 @default.
- W4230507488 hasConcept C121608353 @default.
- W4230507488 hasConcept C126322002 @default.
- W4230507488 hasConcept C143998085 @default.
- W4230507488 hasConcept C2775930923 @default.
- W4230507488 hasConcept C2777701055 @default.
- W4230507488 hasConcept C2780057760 @default.
- W4230507488 hasConcept C530470458 @default.
- W4230507488 hasConcept C71924100 @default.
- W4230507488 hasConcept C72563966 @default.
- W4230507488 hasConceptScore W4230507488C121608353 @default.
- W4230507488 hasConceptScore W4230507488C126322002 @default.
- W4230507488 hasConceptScore W4230507488C143998085 @default.
- W4230507488 hasConceptScore W4230507488C2775930923 @default.
- W4230507488 hasConceptScore W4230507488C2777701055 @default.
- W4230507488 hasConceptScore W4230507488C2780057760 @default.
- W4230507488 hasConceptScore W4230507488C530470458 @default.
- W4230507488 hasConceptScore W4230507488C71924100 @default.
- W4230507488 hasConceptScore W4230507488C72563966 @default.
- W4230507488 hasIssue "15_suppl" @default.
- W4230507488 hasLocation W42305074881 @default.
- W4230507488 hasOpenAccess W4230507488 @default.
- W4230507488 hasPrimaryLocation W42305074881 @default.
- W4230507488 hasRelatedWork W2224319365 @default.
- W4230507488 hasRelatedWork W2603750384 @default.
- W4230507488 hasRelatedWork W2621592748 @default.
- W4230507488 hasRelatedWork W2982645126 @default.
- W4230507488 hasRelatedWork W3132367902 @default.
- W4230507488 hasRelatedWork W3164806321 @default.
- W4230507488 hasRelatedWork W3181412252 @default.
- W4230507488 hasRelatedWork W4220728021 @default.
- W4230507488 hasRelatedWork W4236050426 @default.
- W4230507488 hasRelatedWork W4322775203 @default.
- W4230507488 hasVolume "37" @default.
- W4230507488 isParatext "false" @default.
- W4230507488 isRetracted "false" @default.
- W4230507488 workType "article" @default.